Back To: Home : Featured Technology : Flow Cytometry

CLICK HERE FOR WHAT'S NEW IN:
 

Three-component cancer vaccines
09-10-2007
by Randall C Willis  |  Email the author
SHARING OPTIONS:

ATHENS, Ga.—In developing vaccines against various cancers, researchers would like to take advantage of the aberrant saccharide or glycopeptides signatures of tumor cells. Unfortunately, because these sugars are self-antigens, they elicit poor B-cell responses that are easily swamped by the body's reaction to the carbohydrate carrier proteins like BSA. Recently, researchers at the University of Georgia developed a tripartite vaccine that overcomes these problems.
 
As they describe in Nature Chemical Biology, the researchers synthesized vaccine candidates comprised of tumor-associated carbohydrate B epitopes, promiscuous peptide T-helper (Th) epitopes, and Toll-like receptor (TLR) ligands. Using microtiter assays and flow cytometry, they noted that immunized mice showed high IgG titers against the sugar (MUC1) but not the Th epitope, suggesting they had solved the carrier-induced immune suppression.
 
The researchers also noted that the candidates induced strong cytokine responses, facilitating immune cell maturation. Furthermore, the TLR ligands greatly facilitated uptake by antigen-presenting cells (APCs), which assists with antigen processing and full activation.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.